NASDAQ
|
Healthcare
|
Drug Manufacturers—Specialty & Generic
Q122reported Mar 31, 2022 Reporting Period
$15.08M-68.5%
vs. Q121
Revenues Q122
80.69%60.2%
vs. Q121
Gross Profit Margin
-1000%
!-97.4%
vs. Q121 Net Profit Margin
-320.75M !12.9%
vs. Q121
Free Cash Flow Q122
$-5.16 !10.7%
vs. Q121
EPS Q122
Period
Profitable?
Revenue Growth?
Net Profit Growth?
FCF Growth?
OCF Growth?
EPS Growth?
Pays Dividend?
Q122
Q123
Q123reported Sep 30, 2022 Reporting Period
$49.26M
-18%
vs. Q122
Revenues Q123
-3.47%-108.2%
vs. Q122 Gross Profit Margin
-104.75%
!-429.8%
vs. Q122 Net Profit Margin
-36.69M !
-61.8% vs. Q122 Free Cash Flow Q123
$-0.17 !
-183.3% vs. Q122 EPS Q123
-
Period
Profitable?
Revenue Growth?
Net Profit Growth?
FCF Growth?
OCF Growth?
EPS Growth?
Pays Dividend?
Q122
Q123
Ratios
As of
Mar 31, 2022
Sep 30, 2022
Quick Ratio
3.68
2.48
Current Ratio
4.79
4.07
Cash Ratio
3.4
2.2
Price to Book
6.04
0.83
Price to Sales
100
9.37
Price to Earnings
-4.81
-2.24
Feedback
Disclaimer
The content of this website is for informational purposes only, you should not construe any such information or other material as legal, tax, investment,
financial, or other advice. Nothing contained on this website constitutes professional and/or financial advice, nor does any information on the website constitute a comprehensive or complete statement of the matters discussed or the law relating thereto.
In order to make the best financial decision that suits your own needs, you must conduct your own research and seek the advice of a licensed financial advisor if necessary.
Data
The financial data on StocksFin comes directly from SEC.gov.
We use a third party service (financialmodelingprep) to crawl, reprocess and organize such data in a readable manner. If you encounter any inacurracy in the data, please let us know.
We use Google Analytics to track users sessions on this website. You can block such tracking by using a GA opt-out add-on.
